Search Results
Your search for ,had matches 18497 pages
Showing 1251 - 1300Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) Congress 2024, updates of pivotal neoadjuvant studies demonstrated the long-standing benefit of...
Capmatinib in MET Exon 14–Mutated NSCLC
As reported in The Lancet Oncology by Wolf et al, the final results of the phase II GEOMETRY mono-1 trial support the activity of the kinase inhibitor capmatinib in patients with non–small cell lung cancer (NSCLC) with MET exon 14–skipping mutation (METex14). Study Details The multicohort trial...
Association of Excess Body Weight and Risk of Second Primary Cancers Among Survivors of First Primary Cancers
In a study reported in JAMA Network Open, Bodelon et al found that survivors of first primary cancers with overweight or obesity were at increased risk for second primary cancers, particularly obesity-related cancers. Study Details The study focused on data from the Cancer Prevention Study II...
KEYNOTE-811: Pembrolizumab Combination in First-Line Setting Improves Overall Survival in Gastric Cancer
In the final per-protocol analysis of the phase III KEYNOTE-811 trial, an overall survival benefit was shown by adding the PD-1 inhibitor pembrolizumab to trastuzumab and chemotherapy in treatment-naive, unresectable, HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.1...
Updated Findings in Prostate Cancer Screening With Systemic Biopsy vs MRI-Targeted Biopsy
Updated results of a Swedish screening study (GOTEBORG-2), reported in The New England Journal of Medicine by Hugosson et al, indicate that omitting biopsy among individuals with negative magnetic resonance imaging (MRI) results eliminated a high proportion of diagnoses of clinically insignificant...
Radiation-Associated Secondary Cancers in Breast Cancer Harboring TP53 Germline Pathogenic Variants
In a study published as a research letter in JAMA Oncology, Cederquist et al found that patients with breast cancer who received adjuvant radiation therapy and harbored likely pathogenic TP53 germline variants were at increased risk of developing secondary in-field sarcoma during follow-up. Study...
New Directions in ALL, CML, and CLL Treatment
The Society of Hematologic Oncology (SOHO) 2024 Annual Meeting showcased several groundbreaking studies in the field of hematologic oncology, including key findings in childhood acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). The ASCO...
African Men May Have Higher Risk of Developing Prostate Cancer Earlier
Researchers have identified genetic risk factors that may contribute to prostate cancer in a diverse group of African men, according to a recent study published by Janivara et al in Nature Genetics. The findings could uncover new treatment options in this patient population. Background Certain...
Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer
For women with early-stage triple-negative breast cancer, KEYNOTE-522 changed the treatment paradigm several years ago. Support for neoadjuvant use of the PD-1 inhibitor pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, was bolstered by the positive overall survival analysis...
Sintilimab/Bevacizumab in Relapsed or Persistent Ovarian Clear Cell Carcinoma
In a Chinese phase II trial (INOVA) reported in The Lancet Oncology, Peng et al found that the combination of sintilimab and bevacizumab showed activity in patients with relapsed or persistent ovarian clear cell carcinoma. Study Details In the multicenter trial, 37 evaluable patients with exposure...
FDA Approves Inavolisib Combination in PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
The U.S. Food and Drug Administration (FDA) approved the PI3K inhibitor inavolisib (Itovebi) with the CDK4/6 inhibitor palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer, as...
Global Disparities May Exist in Availability, Timeliness of New Cancer Drugs
Despite considerable progress in the discovery and development of new cancer drugs between 1990 and 2022, there may be disparities in both the availability and timeliness of these treatment options globally, particularly among lower-income countries, according to a recent study published by Li et...
Can Blood Test Predict Survival in Metastatic Prostate Cancer?
A recent study found that measuring circulating tumor cells (CTCs) is a reliable way to predict later treatment response and survival prospects in men when metastatic prostate cancer is first diagnosed. The test may help providers to decide which patients should receive standard treatment vs who...
Novel Cell Therapy May Offer Benefit in Patients With Relapsed or Refractory T-Cell ALL
A novel cell therapy targeting CD7 on leukemia cells may provide an effective treatment option for patients with refractory T-cell acute lymphoblastic leukemia (ALL), according to a recent study published by Oh et al in Nature Medicine. The findings highlighted the effectiveness of a new chimeric...
Exercise Linked to Fewer Falls in Older Adults With Cancer
A recent study suggests that for people older than age 65 who have cancer, physical activity may be key to reducing the chances of a dangerous fall. People with lung cancer, colorectal cancer, or prostate cancer, in particular, had a lower risk of falling when they talked with their doctor...
Transperineal vs Transrectal Prostate Biopsy for Suspicion of Prostate Cancer
In the PREVENT trial, reported as a research letter in JAMA Oncology, Hu et al found that transperineal prostate biopsy resulted in less risk of infection than transrectal biopsy in patients with suspicion of prostate cancer, with no difference between methods observed in detecting high-grade...
Sexual Health and Quality of Life With Simple vs Radical Hysterectomy in Low-Risk, Early-Stage Cervical Cancer
In an analysis from the phase III SHAPE trial reported in the Journal of Clinical Oncology, Ferguson et al found that simple hysterectomy was associated with a reduced risk of sexual dysfunction vs radical hysterectomy in patients with low-risk, early-stage cervical cancer. The trial showed...
ACA’s Dependent Coverage Expansion May Have Benefited Young Adult Patients Diagnosed With Cancer
Investigators have uncovered that during the Patient Protection and Affordable Care Act’s (ACA) first decade, the survival rates of Dependent Coverage Expansion–eligible young adult patients with cancer may have improved, according to a recent study published by Roth et al in Cancer. The federal...
Addition of Liver Transplantation to Chemotherapy for Permanently Unresectable Colorectal Cancer Liver Metastases
In the European TransMet trial, reported in The Lancet, Adam et al found that liver transplantation plus chemotherapy improved overall survival vs chemotherapy alone in patients with permanently unresectable colorectal cancer liver metastases. Study Details In the open-label trial, 94 patients...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More
The ASCO Annual Meeting brings together oncologists, researchers, and health-care professionals to share the latest advancements in cancer care. The 2024 ASCO Annual Meeting (ASCO24) was particularly momentous for those of who received the international development and education award (IDEA). As...
Coping With the Risk of Hereditary Cancer
Three years ago, it had become clear that I needed to be tested for the BRCA1/2 mutation. I knew my family history of cancer was not good. My paternal grandmother died of breast cancer when she was just 41, and her mother had likely died of cervical cancer when she was in her 50s. More recently,...
Two U.S. Scientists Named Recipients of the 2024 Nobel Prize in Physiology or Medicine
The 2024 Nobel Prize in Physiology or Medicine has been awarded jointly to two U.S. scientists: Victor Ambros, PhD, and Gary Ruvkun, PhD, for the discovery of microRNA and its role in post-transcriptional gene regulation. The recipients were named in a news release issued by The Nobel Assembly at ...
PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...
LEAP-012: Combination of Therapies Extends Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma
The combination of the VEGF tyrosine kinase inhibitor lenvatinib, the PD-1 inhibitor pembrolizumab, and transarterial chemoembolization (TACE) significantly improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma (HCC) compared with TACE alone, according to...
AI Language Models May Generate Effective Physician's Letters
An artificial intelligence (AI) algorithm may be effective at writing physician’s letters, according to a recent study published by Heilmeyer et al in JMIR Medical Informatics. Background According to recent surveys, physicians may spend almost 3 hours per day on documentation activities. “The...
DESTINY-Breast12: T-DXd of Benefit in Patients With Breast Cancer and Brain Metastases
Late-breaking findings from the phase IIIb/IV, open-label DESTINY-Breast12 trial support the use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive metastatic breast cancer and brain metastases who have experienced disease progression on at least...
‘Encouraging’ Pathologic Responses Achieved With Novel Combination Regimen in Early-Stage NSCLC
In the multiarm phase II NeoCOAST-2 trial, neoadjuvant treatment with datopotamab deruxtecan (Dato-DXd) plus the monoclonal antibody durvalumab and single-agent platinum chemotherapy led to promising rates of pathologic complete and major pathologic responses in patients with early-stage non–small...
NO-CUT Trial: Nonoperative Management of Benefit for Many Patients With Rectal Cancer
Total neoadjuvant therapy (TNT) followed by rectal surgery is the standard of care in proficient mismatch repair (pMMR) locally advanced rectal cancer, but studies are finding that patients with clinical complete response may often avoid surgery and be followed “nonoperatively.” In the first...
Novel Radioconjugate or Conventional Care Prior to Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory AML
As reported in Journal of Clinical Oncology by Gyurkocza et al, the phase III SIERRA trial has shown higher rates of durable complete remissions with the anti-CD45 radioconjugate iodine-131–apamistamab vs conventional care followed by allogeneic hematopoietic cell transplantation (allo-HCT) in...
Atezolizumab Plus Platinum Doublet and Maintenance Niraparib for Late-Relapsing Recurrent Ovarian Cancer
As reported in the Journal of Clinical Oncology by González-Martín et al, a phase III trial (ENGOT-OV41/GEICO 69-O/ANITA) has shown no progression-free survival benefit with the addition of atezolizumab to a carboplatin doublet and maintenance niraparib in patients with recurrent ovarian cancer...
Spiritual Themes, Distrust May Factor Into Black Patients’ Reluctance to Participate in Cancer Clinical Trials
Spiritual beliefs and a historically based distrust of clinical research may influence Black patients’ decisions about whether to participate in cancer trials, according to new findings presented by Gomez et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract...
Radiopharmaceutical Therapy May Offer Benefit in Patients With Refractory Meningioma
A radiopharmaceutical therapy has demonstrated early efficacy in patients with difficult-to-treat meningioma, according to new findings presented by Merrell et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 2) and simultaneously published in the...
Certain KRAS Gene Mutations Linked to Improved Prognosis in Pancreatic Cancer
A common mutation in the KRAS gene seems to be associated with improved overall survival in pancreatic ductal adenocarcinoma compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a recent study published in...
FDA Approves Perioperative Nivolumab for Resectable NSCLC
On October 3, 2024, the U.S. Food and Drug Administration approved nivolumab (Opdivo) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors ≥ 4 cm and/or node-positive) non–small cell...
Strategies for Recovering Neurocognitive Function After Cranial Radiation Therapy
A substantial number of patients with brain metastases who experience cognitive side effects after radiation therapy may fully regain cognitive function, according to recent findings presented by Cherng et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 150). ...
Conversations on Cancer: Exploring Religious Literacy and Spirituality in Cancer Care
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Clark Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team, ...
Duration of Postmastectomy Radiation Therapy in Patients Planning Breast Reconstruction
An accelerated course of postmastectomy radiation therapy may not increase complications in patients with breast cancer undergoing breast reconstruction, according to recent findings presented by Poppe et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 1) and ...
HIMALAYA: 5-Year Analysis Confirms Survival Benefit of STRIDE Regimen in Hepatocellular Carcinoma
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, confirms the benefit for the STRIDE regimen of the monoclonal antibodies durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.1 [The STRIDE regimen consists of a single priming dose of...
ACS Report: Despite Overall Decreases in Breast Cancer Mortality, Incidence Rising in Key Groups
The American Cancer Society (ACS) recently released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States. The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately...
Addition of Nivolumab to Tivozanib Following Immune Checkpoint Inhibitor Treatment in Metastatic Renal Cell Carcinoma
As reported in The Lancet by Choueiri et al, the phase III TiNivo-2 trial has shown that immune checkpoint inhibitor rechallenge with nivolumab plus tivozanib did not improve progression-free survival vs tivozanib alone in patients with metastatic renal cell carcinoma following immune checkpoint...
Standard Chemoradiation May Be Superior to Deintensification Approaches in Patients With HPV-Associated Oropharyngeal Cancer
Deintensified treatment involving a lower radiation dose and immunotherapy in place of chemotherapy may not perform as well as a more rigorous chemoradiation treatment approach in patients with early-stage human papillomavirus (HPV)-associated oropharyngeal cancer, according to new findings...
Intensity-Modulated Radiation Therapy and Proton-Beam Therapy May Offer Equally High Quality of Life and Tumor Control in Patients With Localized Prostate Cancer
Two types of contemporary radiation therapy—proton-beam therapy or intensity-modulated radiation therapy—may provide comparable rates of tumor control with no differences in patient-reported quality of life among patients with low- and intermediate-risk prostate cancer, according to new findings...
EMBER: Imlunestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
In the the phase IA/B dose-escalation and -expansion EMBER study reported in the Journal of Clinical Oncology by Jhaveri et al, the next-generation oral selective estrogen receptor degrader imlunestrant (alone and in combination with other targeted therapies) demonstrated a manageable safety...
Amivantamab-vmjw Plus Lazertinib Improves Long-Term Outcomes in First-Line Setting of EGFR-Mutant Advanced NSCLC
The combination of the EGFR-MET bispecific antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib continues to demonstrate superior efficacy compared with the kinase inhibitor osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...
Updated Findings With Belzutifan in von Hippel-Lindau Disease–Associated CNS Hemangioblastomas
As reported in The Lancet Oncology by Iliopoulos et al, updated findings from the phase II LITESPARK-004 trial support the efficacy of belzutifan in patients with von Hippel-Lindau (VHL) disease–associated CNS hemangioblastomas. Study Details In the study, 50 patients with CNS hemangioblastomas...
Quality Improvements in Lung Cancer Surgery and Tumor Pathology May Extend Survival Postsurgery
Advancing surgical and pathologic techniques may improve overall survival rates in high-risk patients with lung cancer, according to new findings presented by Akinbobola et al at the 2024 ASCO Quality Care Symposium (Abstract 278). Background “Over the past 15 years, a quality improvement...
Conversations Between Physicians and Older Patients About Physical Activity May Reduce Falls During Cancer Treatment
Communication between health-care providers and older patients with cancer regarding the significance of physical activity may help reduce the risk of falls during cancer therapy, according to new findings presented by Lu and Zheng at the 2024 ASCO Quality Care Symposium (Abstract 224). Background...
CABINET Trial Supports Multitargeted Tyrosine Kinase Inhibitor for Advanced Neuroendocrine Tumors
As reported in The New England Journal of Medicine by Chan et al, the multicenter phase III CABINET trial has shown significantly improved progression-free survival with the multitargeted tyrosine kinase inhibitor cabozantinib vs a placebo in previously treated patients with progressive, advanced...
Community-Academic Partnership May Successfully Reduce Radon-Related Lung Cancer Risk in Native Population
A community and academic partnership may provide effective education about the risks of radon, testing for radon, mitigating radon in homes with high levels of the chemical, and reducing the risk of developing lung cancer among Native community members residing in Wisconsin, according to new...
Datopotamab Deruxtecan vs Docetaxel in Previously Treated Advanced or Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Ahn et al, the phase III TROPION-Lung01 trial showed significantly improved progression-free survival—but not overall survival—with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel in patients with...
